Adaptive Biotechnologies (ADPT) CCO Benzeno receives 39,063-share stock award

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp reported that Chief Commercial Officer, Immune Medicine, Sharon Benzeno acquired 39,063 shares of common stock on March 4, 2026 through a grant or award at a stated price of $0.00 per share. Following this award, Benzeno directly holds 335,854 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENZENO SHARON

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Ofc Imm Med

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		39,063	A	$0	335,854	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADPT report for Sharon Benzeno?

Adaptive Biotechnologies reported that Chief Commercial Officer, Immune Medicine, Sharon Benzeno received a grant of 39,063 shares of common stock. The transaction occurred on March 4, 2026 and was recorded as a grant, award, or other acquisition, not an open‑market purchase.

How many Adaptive Biotechnologies (ADPT) shares did Sharon Benzeno acquire?

Sharon Benzeno acquired 39,063 shares of Adaptive Biotechnologies common stock. The acquisition was classified as a grant or award with a stated price of $0.00 per share, indicating it was not a cash market purchase but an equity-based compensation transaction.

What is Sharon Benzeno’s total ADPT share ownership after this transaction?

After the reported grant, Sharon Benzeno directly holds 335,854 shares of Adaptive Biotechnologies common stock. This total reflects her ownership immediately following the March 4, 2026 award of 39,063 shares classified as a grant, award, or other acquisition in the Form 4 filing.

Was the ADPT transaction by Sharon Benzeno a stock purchase or an award?

The transaction was an award, not a market purchase. It is coded as a grant, award, or other acquisition and shows a price of $0.00 per share, indicating shares were issued to Sharon Benzeno as part of compensation rather than bought on the open market.

What role does Sharon Benzeno hold at Adaptive Biotechnologies (ADPT)?

Sharon Benzeno serves as Adaptive Biotechnologies’ Chief Commercial Officer for Immune Medicine. In this capacity, she reported receiving a grant of 39,063 common shares, bringing her direct holdings to 335,854 shares according to the disclosed Form 4 insider transaction data.

On what date did Sharon Benzeno’s ADPT share grant occur?

The grant of 39,063 Adaptive Biotechnologies common shares to Sharon Benzeno took place on March 4, 2026. This date is listed as the transaction date for the award, which increased her directly held position to a total of 335,854 common shares afterward.